HURA Stock Overview
Operates as a biotechnology company that develops novel cell and gene therapies based on distinct and synergistic technology platforms. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
TuHURA Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.05 |
| 52 Week High | US$7.93 |
| 52 Week Low | US$2.92 |
| Beta | 0 |
| 11 Month Change | -3.63% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -19.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| HURA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 53.5% | 4.0% | 2.0% |
| 1Y | n/a | 18.0% | 32.4% |
Return vs Industry: Insufficient data to determine how HURA performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how HURA performed against the US Market.
Price Volatility
| HURA volatility | |
|---|---|
| HURA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: HURA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine HURA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 1 | Jim Bianco | tuhurabio.com |
TuHURA Biosciences, Inc. operates as a biotechnology company that develops novel cell and gene therapies based on distinct and synergistic technology platforms. The company owns and develops a product portfolio of cellular and gene therapies that can detect, monitor, and control cancer. It offers ImmuneFx, a cancer vaccine; Morphogenesis Allograft Tissue with Compatible HLA (MATCH) stem cell banks; Polymer Antibody Cell Separation System (PACS), a device that captures and releases viable targeted cells from large volumes; and BlueBio, a program for mining microbial compounds from the ocean floor.
TuHURA Biosciences, Inc. Fundamentals Summary
| HURA fundamental statistics | |
|---|---|
| Market cap | US$146.69m |
| Earnings (TTM) | -US$19.33m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-11.0x
P/E RatioIs HURA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HURA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$19.33m |
| Earnings | -US$19.33m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.46 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -880.5% |
How did HURA perform over the long term?
See historical performance and comparison